Pulmonx Corporation — FY2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021. This is an annual filing; separate fourth-quarter financial results are not clearly provided in the filing text. The company is a commercial-stage medical technology business whose revenue is primarily from Zephyr Endobronchial Valves and delivery catheters for severe emphysema. Its solution also includes the Chartis assessment system and StratX lung-analysis platform.
Key financial results
| Metric | FY2021 | FY2020 |
|---|---|---|
| Revenue | $48.4 million | $32.7 million |
| Gross profit / gross margin | $35.6 million / 73.6% | $21.2 million / 64.8% |
| Operating expenses | $82.9 million | $53.5 million |
| Operating loss | $47.3 million | $32.3 million |
| Net loss | $48.7 million | $32.2 million |
| Cash used in operations | $41.4 million | $30.6 million |
- Revenue rose 47.9%. U.S. revenue was $25.0 million and international revenue was $23.4 million; each increased year over year. International sales were 48.4% of total revenue, versus 50.5% in 2020.
- Gross margin expanded as higher procedure volumes improved manufacturing utilization and operating leverage. Research and development expense increased 75.1% to $13.1 million; selling, general and administrative expense increased 51.6% to $69.9 million.
- At year-end, cash and cash equivalents were $148.5 million and marketable securities were $42.5 million, totaling $191.0 million. Accumulated deficit was $291.4 million.
- Net cash used in investing activities was $46.3 million, principally reflecting purchases of marketable securities and $3.7 million of property and equipment. Financing activities provided $4.5 million, mainly from employee stock purchases and option exercises; FY2020 financing included $201.4 million of net IPO proceeds.
- Debt included a $17.0 million CIBC term loan, reported net of discount at $16.9 million, and a Swiss credit agreement. CIBC principal payments were scheduled to begin in February 2023; the loan matures in February 2025. The company reported covenant compliance at year-end.
Material changes and operating context
- Revenue growth reflected higher Zephyr Valve sales as the company gradually recovered from COVID-19 disruptions and expanded commercialization. Procedure volumes remained uneven: Delta and Omicron affected some U.S. regions in the second half, and European lockdowns pressured international business in the fourth quarter.
- Operating losses widened as the company expanded its sales and marketing organization, increased advertising, and invested more in clinical trials, research and development, and public-company infrastructure.
- FY2020 included IPO-related and other unusual financing effects, including favorable changes in derivative fair value; these contributed to the year-over-year change in other income (expense). The 2020 notes converted to common stock in connection with the IPO.
Outlook, risks and contingencies
- Management provided no specific revenue or earnings guidance in the supplied filing text. It expects continued losses and negative operating cash flows for the foreseeable future, while stating that available cash, cash equivalents and marketable securities are expected to fund planned operations for at least 12 months from issuance of the financial statements.
- COVID-19-related procedure delays and hospital capacity constraints may persist. Other key risks include dependence on the Zephyr Valve and severe-emphysema indication, adoption and reimbursement uncertainty, competition, and reliance on single-source suppliers and a primary manufacturing site.
- Zephyr Valve treatment carries material clinical risks, particularly pneumothorax. In the LIBERATE pivotal study, pneumothorax occurred in 26.6% of treated patients during the first 45 days; four treatment-period deaths in the valve group were considered definitely or probably treatment-related by investigators. Current practice is to monitor patients in hospital for at least three nights after treatment.
- The company is developing AeriSeal for patients not eligible for Zephyr Valve treatment because of collateral ventilation. It had FDA Breakthrough Device designation, but further study and regulatory authorization are required; the company said it intended to submit an IDE for a clinical trial.
- Management identified a material weakness in financial-reporting controls involving user access and segregation of duties in certain IT systems related to expenditures. Management concluded controls were ineffective at year-end; the auditor issued an adverse opinion on internal control over financial reporting. The financial-statement audit opinion was unqualified, and management reported no resulting material misstatement in the periods presented. Remediation was underway, not yet complete.
- The filing describes lawsuits involving a former distributor and the company’s Swiss subsidiary, while stating the claims were believed to be without merit and not expected to be material. Item 3 states the company was not party to material legal proceedings.
Important facts for investors to verify
- Whether procedure volumes and revenue growth continue as COVID-related disruptions ease, particularly in the U.S. and Europe.
- Whether gross-margin gains persist as sales scale, and how spending growth affects losses and cash burn.
- Progress in broadening commercial-payor coverage and maintaining Medicare access on a case-by-case basis.
- Cash runway assumptions, CIBC loan terms and covenants, and the timing of required debt repayments.
- Clinical safety and long-term effectiveness data, including required LIBERATE follow-up, and the status and timing of AeriSeal studies.
- Remediation and independent validation of the material weakness in internal controls, and any developments in the former-distributor litigation.